Philippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus
|
|
- Catherine Hicks
- 6 years ago
- Views:
Transcription
1 Philippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus Iris Thiele Isip Tan MD, MSc, FPCP, FPSEM Chief, Medical Informatics Unit Associate Professor IV, UP College of Medicine Adapted from the presentation of Dr. Cecilia Jimeno
2 UNITE FOR DIABETES PHILIPPINES Diabetes Philippines Institute for Studies on Diabetes Foundation, Inc. Philippine Society of Endocrinology & Metabolism Philippine Center for Diabetes Education Foundation, Inc.
3 UNITE FOR DIABETES PHILIPPINES Goals & Areas of Collaboration Encourage best diabetes practices - development of a unified CPG Establishment of a national diabetes database Spearhead the fight for patients rights & safety - vigilance on false claims
4 UNITE FOR DIABETES PHILIPPINES Objectives for the Clinical Practice Guideline To develop clinical practice guidelines on the screening, diagnosis and management of diabetes which reflect the current best evidence and which incorporate local data into the recommendations, in view of aiding clinical decision making for the benefit of the Filipino patient GUIDELINES THAT ARE SUITED FOR LOCAL REALITIES
5 UNITE FOR DIABETES PHILIPPINES Organizations in the Consensus Panel Diabetes Philippines Institute for Studies on Diabetes Foundation, Inc. Philippine Society of Endocrinology & Metabolism Philippine Center for Diabetes Education Foundation, Inc. 23 other specialty, subspecialty organizations lay representatives of persons with diabetes
6 Scope of the Philippine CPG development Screening and diagnosis Screening for complications Outpatient setting Prevention and treatment Special groups: GDM, elderly
7 Philippine Clinical Practice Guideline for Diabetes Mellitus Part 1: SCREENING & DIAGNOSIS
8 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Statement 2.1 All individuals being seen at any physician s clinic or by any healthcare provider should be evaluated annually for risk factors for type 2 diabetes. (Table 1) [Grade D, Level 5]
9 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Statement 2.2 Universal screening using laboratory tests is NOT recommended as it would identify very few individuals who are at risk. [Grade D, Level 5]
10 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Table 1. Demographic and Clinical Risk Factors for Type 2 Diabetes Testing should be considered in all adults >40 years old.
11 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Consider earlier testing if with at least one other risk factor as follows: history of IGT or IFG history of GDM or delivery of a baby weighing 8 lbs or above polycystic ovary syndrome (PCOS) overweight (BMI >23 kg/m 2 ) or obese (BMI >25 kg/m 2 ) waist circumference >80 cm ( ) and >90 cm ( ) or waist-hip ratio (WHR) >1 ( ) and >0.85 ( )
12 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Consider earlier testing if with at least one other risk factor as follows (con t): first-degree relative with type 2 diabetes sedentary lifestyle hypertension (BP >140/90 mm Hg) diagnosis or history of any vascular diseases including stroke, peripheral arterial occlusive disease, coronary artery disease
13 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Consider earlier testing if with at least one other risk factor as follows (con t): acanthosis nigricans schizophrenia serum HDL <35 mg/dl (0.9 mmol/l) and/or serum triglycerides >250 mg/dl (2.82 mmol/l)
14 Which of the following will you NOT screen for diabetes? a.42/f on follow-up for hypertension b.35/m consulting for cough c.45/m with tuberculosis d.28/f diagnosed with PCOS
15 Why 40? Recommendation from other guidelines ADA 2010 CDA 2008 AACE 2007 IDF 2005 All >45 y (B) Earlier if BMI >25 kg/m2 and with >1 risk factor(s) (B) All > 40 y Earlier if with risk factors >30 y with risk factor (B) Target high risk people by risk factor assessment
16 Why 40? NNHeS 2008 Prevalence of Diabetes Mellitus Age (y) Based on FBS a Based on 2h postprandial glucose Based on DM questionnaire True Diabetes > Overall a Based on FBS >125 mg/dl b Based on 2h-PPG > 200 mg/dl c Based on DM questionnaire (previous diagnosis by nurse or physician or on medication) d True diabetes (positive in any of the three assessment methods
17 You screen the 42 y.o. hypertensive. FBS is 5.2 mmol/l. What next? a.reassure patient she is not diabetic. There is no need to repeat the test. b.repeat FBS after 1 year. c.order an OGTT after 6 months. d.ask for an HbA1c after 3 months.
18 If initial test(s) are negative, when should repeat testing be done? Repeat testing should ideally be done annually for Filipinos with risk factors owing to the significant prevalence and burden of diabetes in our country. (Level 5, Grade D)
19 CANDI Manila Fojas MC, Lantion-Ang FL, Jimeno CA, Santiago D, Arroyo M, Laurel A, Sy H, See J. Complications and cardiovascular risk factors among newly-diagnosed type 2 diabetics in Manila. Phil. J. Internal Medicine, 47: , May-June, 2009 Local study: newly-diagnosed diabetics in Manila 20% peripheral neuropathy 42% proteinuria 2% diabetic retinopathy COMPLICATIONS FOUND AT DIAGNOSIS!
20 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Recommended tests for diagnosing diabetes: Fasting plasma glucose (FPG) hours Random plasma glucose (RPG) 2-h plasma glucose in 75-g OGTT
21 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Criteria for diagnosis of diabetes (Level 2, Grade B) FPG >126 mg/dl (7.0 mmol/l) Random plasma glucose >200 mg/dl (11.1 mmol/l) in a patient with classic symptoms of hyperglycemia (weight loss, polyuria, polyphagia, polydipsia) or with signs and symptoms of hyperglycemic crisis 2-h plasma glucose in 75-g OGTT >200 mg/dl (11.1 mmol/l)
22 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Fasting plasma glucose (FPG) is the preferred test due to its wide availability, lower cost and better reproducibility (Level 3, Grade B) If the FPG falls within the impaired fasting glucose range ( mmol/l) then a 75-g OGTT is recommended (Level 3, Grade B) Symptomatic patients - random or FPG
23 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Among asymptomatic individuals with positive results, any of the three tests should be repeated within two weeks for confirmation (Level 4, Grade C).
24 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Diabetes can be diagnosed when any of the three tests are positive in a symptomatic patient (weight loss, polyuria, polyphagia, polydipsia).
25 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS A 75-g OGTT is preferred as the first test for the following (Level 3, Grade B): Previous FBS showing IFG mg/dl ( mmol/l) Previous diagnosis of CVD (CAD, stroke, peripheral arteriovascular disease) or who are at high risk of CVD A diagnosis of Metabolic Syndrome
26 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS At the present time, we cannot recommend the routine use of the following tests in the diagnosis of diabetes (Level 3, Grade C): HbA1c Capillary blood glucose Fructosamine Urinalysis (Level 3, Grade B) Plasma insulin (Level 3, Grade B)
27 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS HbA1c Capillary blood glucose Fructosamine Urinalysis Interpret an available result with caution and confirm with any of the three standard tests (Level 2, Grade B).
28 Why NOT Hba1C? Until standardization has been done in the Philippines, use HbA1c only as a tool for monitoring control among those with established DM. HbA1c not readily available in some areas NGSP certification not easily verified in laboratories Studies needed to determine effect of ethnicity
29 You screen the 42 y.o. hypertensive. FBS is 5.2 mmol/l. What next? a.reassure patient she is not diabetic. There is no need to repeat the test. b.repeat FBS after 1 year. c.order an OGTT after 6 months. d.ask for an HbA1c after 3 months.
30 Algorithm for Screening Diabetes Among Asymptomatic Individuals Screen for risk factors for DM, prediabetes and MetS
31 Algorithm for Screening Diabetes Among Asymptomatic Individuals Screen for risk factors for DM, prediabetes and MetS YES Risk factors (Table 1)
32 Algorithm for Screening Diabetes Among Asymptomatic Individuals Screen for risk factors for DM, prediabetes and MetS YES Risk factors (Table 1) YES Lab testing using FBS, RBS, OGTT (Fig 3)
33 Algorithm for Screening Diabetes Among Asymptomatic Individuals Screen for risk factors for DM, prediabetes and MetS YES Risk factors (Table 1) NO Age >40 y YES YES Lab testing using FBS, RBS, OGTT (Fig 3)
34 Algorithm for Screening Diabetes Among Asymptomatic Individuals Screen for risk factors for DM, prediabetes and MetS YES Risk factors (Table 1) NO Age >40 y NO No further testing; re-evaluate annually for risk factors YES YES Lab testing using FBS, RBS, OGTT (Fig 3)
35 Age >40 y Age <40 y with risk factors for DM No 3 P s or weight loss (asymptomatic) No known CAD, PAD, CVD, No MetS Diagnosed CAD, PAD, CVD or with MetS Symptomatic (polyuria, polydipsia, polyphagia, weight loss)
36 Age >40 y Age <40 y with risk factors for DM No 3 P s or weight loss (asymptomatic) No known CAD, PAD, CVD, No MetS Diagnosed CAD, PAD, CVD or with MetS Symptomatic (polyuria, polydipsia, polyphagia, weight loss) Fasting plasma glucose <100 mg/dl mg/dl >126 mg/dl No diabetes Repeat testing after 1 y 75-g OGTT Diabetes
37 Age >40 y Age <40 y with risk factors for DM No 3 P s or weight loss (asymptomatic) No known CAD, PAD, CVD, No MetS <100 mg/dl Fasting plasma glucose mg/dl >126 mg/dl Diagnosed CAD, PAD, CVD or with MetS FBS <100 & 2h <140 mg/dl 75-g oral glucose tolerance test (OGTT) FBS or 2h mg/dl FBS >126 mg/dl or 2h >200 Symptomatic (polyuria, polydipsia, polyphagia, weight loss) No diabetes Repeat testing after 1 y 75-g OGTT Diabetes No diabetes Repeat testing after 1 y IFG or IGT Repeat after 6 mos Diabetes
38 Age >40 y Age <40 y with risk factors for DM No 3 P s or weight loss (asymptomatic) No known CAD, PAD, CVD, No MetS <100 mg/dl Fasting plasma glucose mg/dl >126 mg/dl Diagnosed CAD, PAD, CVD or with MetS FBS <100 & 2h <140 mg/dl 75-g oral glucose tolerance test (OGTT) FBS or 2h mg/dl FBS >126 mg/dl or 2h >200 Symptomatic (polyuria, polydipsia, polyphagia, weight loss) <140 mg/dl Random plasma glucose mg/dl >200 mg/dl No diabetes Repeat testing after 1 y 75-g OGTT Diabetes No diabetes Repeat testing after 1 y IFG or IGT Repeat after 6 mos Diabetes No diabetes Repeat testing after 1 y 75-g OGTT Diabetes
39 Philippine Clinical Practice Guideline for Diabetes Mellitus Part 2: MANAGEMENT & MONITORING
40 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Initial evaluation - comprehensive medical history and PE Coronary heart disease risk assessment Foot evaluation: assess risk for foot ulcer (identify high-risk feet) Eye exam: fundoscopy on diagnosis Dental history or oral health history
41 RED FLAGS of dental disease tooth ache pain when chewing sensitivity to cold/hot drinks badly broken teeth swelling of gums bad breath
42 PERIODONTITIS gum bleeding on brushing swelling and redness of gums looseness or mobility of teeth Prevalence among T2DM 68% (SLMC, n =192) Bitong et al PJIM 2010 teeth that fall off in adults
43 Which of the following will you NOT request as initial tests for a person with diabetes? a.fasting blood glucose, HbA1c b.complete lipid profile c.blood uric acid, 12-lead ECG d.alt, AST, serum creatinine
44 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Minimal initial tests to be requested Fasting blood glucose, complete lipid profile HbA1c Liver function tests Urinalysis; spot urine albumin-to-creatinine ratio Serum creatinine and calculated GFR
45 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Optional tests ECG and TET TSH in type 1 diabetes, dyslipidemia or women over age 50 y
46 Which of the following will you NOT request as initial tests for a person with diabetes? a.fasting blood glucose, HbA1c b.complete lipid profile c.blood uric acid, 12-lead ECG d.alt, AST, serum creatinine
47 Which of the following statements is true about monitoring diabetes? a. Monitor Hba1c ideally twice a year. b. Check FBS and postprandial blood sugar every 2-4 weeks. c. Estimate trends in blood sugar control by checking CBGs once a week. d. Achieve glycemic goals within three months.
48 Glycemic targets HbA1c <7% FBS <4-7 mmol/l ( mg/dl) 2h PPG <5-10 mmol/l ( mg/dl) Individualize targets. Capillary (ADA) fasting mg/dl PPBG <180 mg/dl
49 Glycemic targets HbA1c <6.5% FBS <6 mmol/l 2h PPG <8 mmol/l Newly diagnosed Relatively young (age <60 y) No complications No risk factors for hypoglycemia Individualize targets.
50 Ideally, HbA1c every 3-6 months; 2x a year if controlled on stable therapy FBS, postprandial sugar every 2-4 weeks Capillary blood glucose 2x a week to estimate trends
51 Glycemic targets should be achieved within 6 months of diagnosis or first prescription.
52 Which of the following statements is true about monitoring diabetes? a. Monitor Hba1c ideally twice a year. b.check FBS and postprandial blood sugar every 2-4 weeks. c. Estimate trends in blood sugar control by checking CBGs once a week. d. Achieve glycemic goals within three months.
53 Targets to Decrease CV Risk Lipid control ASA BP control
54 Which of the following statements is true about reducing CV risk in diabetes? a. Statins should be given regardless of baseline lipid levels. b. There is insufficient evidence to recommend aspirin for primary prevention in men <60 y. c. Give clopidogrel 75 mg/day for those with diabetes and a history of CVD. d. The goal BP for most persons with diabetes is <140/80 mm Hg.
55 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS The goal BP for most persons with diabetes is <140/80 mm Hg. Lifestyle therapy alone for 3 months if pre-hypertensive (SBP mm Hg or DBP mm Hg) Pharmacologic + lifestyle therapy if SBP>140 mm Hg or DBP >90 mm Hg, or pre-hypertensive uncontrolled with lifestyle therapy alone
56 Lifestyle therapy Weight loss if overweight DASH-style dietary pattern (reduce Na, increase K, moderation of alcohol, increased physical activity).
57 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Statement 7.3 ACE inhibitors & ARBs are generally recommended as initial therapy. If one class is not tolerated, the other should be substituted. Multiple drug therapy (>2 agents at maximal doses) is generally required to achieve BP targets. Thiazide-type diuretics, calcium channel blockers and B-blockers may be given as additional agents.
58 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Recommendations are consistent with Philippine Practice Guidelines for the Treatment of Dyslipidemia. LDL is the primary target for dyslipidemia management in persons with diabetes.
59 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Statement Statin therapy should be added to lifestyle therapy, regardless of baseline levels for diabetics with overt CVD (A) without CVD who are >40 y and have >1more other CVD risk factors (A)
60 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Statement For patients at lower risk (e.g. without overt CVD and <40 y), statin therapy should be considered in addition to lifestyle therapy if - LDL-C remains >100 mg/dl those with multiple risk factors (hypertension, familial hypercholesterolemia, LVH, smoking, family history of premature CAD, male sex, age >55 y, proteinuria, albuminuria, BMI>25)
61 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS The rule Without overt CVD, goal is LDL-C <100 mg/ dl (2.6 mmol/l) [A] With overt CVD, goal is LDL-C <70 mg/dl (1.8 mmol/l). Use of high dose statin is an option. [B]
62 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Recommendation 9.2 Insufficient evidence to recommend aspirin for primary prevention in lower risk individuals Men < 50 y Women <60 y * Clinical judgement if with multiple risk factors
63 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Recommendation 9.3 Use aspirin therapy for secondary prevention strategy in those with DM and a history of CVD [A]. For patients with CVD and documented aspirin allergy, clopidogrel (75 mg/day) should be used.
64 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Recommendation 9.4 Combination therapy of ASA ( mg/day) and clopidogrel (75 mg/day) is reasonable up to a year after an acute coronary syndrome [B].
65 Which of the following statements is true about reducing CV risk in diabetes? a. Statins should be given regardless of baseline lipid levels. b. There is insufficient evidence to recommend aspirin for primary prevention in men <60 y. c. Give clopidogrel 75 mg/day for those with diabetes and a history of CVD. d.the goal BP for most persons with diabetes is <140/80 mm Hg.
66 Initiation of Drug Therapy among Newly Diagnosed Type 2 Diabetes Patients Newly diagnosed T2DM
67 Initiation of Drug Therapy among Newly Diagnosed Type 2 Diabetes Patients Newly diagnosed T2DM HbA1c <9% FBS < 250 HbA1c >9% FBS > 250
68 Initiation of Drug Therapy among Newly Diagnosed Type 2 Diabetes Patients Newly diagnosed T2DM HbA1c <9% FBS < 250 HbA1c >9% FBS > 250 Monotherapy Option for combination therapy
69 Initiation of Drug Therapy among Newly Diagnosed Type 2 Diabetes Patients Newly diagnosed T2DM HbA1c <9% FBS < 250 HbA1c >9% FBS > 250 Monotherapy Option for combination therapy Combination therapy Insulin therapy
70 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Statement 10.1 Initiate treatment with metformin for monotherapy unless with contraindications or intolerance of its ADE s - diarrhea severe nausea abdominal pain
71 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS When optimization of therapy is needed, choose the second drug according to the following - degree of HbA1c lowering hypoglycemia risk weight gain patient profile (dosing complexity, renal/hepatic problems, other contraindications and age)
72 Drug Therapy HbA1c reduction (%) MONOTHERAPY Sulfonylureas 0.9 to 2.5 Biguanide (Metformin) 1.1 to 3.0 Thiazolidinedione 1.5 to 1.6 Alpha-glucosidase inhibitors 0.6 to 1.3 DPP-4 inhibitors 0.8 NON-INSULIN INJECTABLE Exenatide 0.8 to 0.9 COMBINATION THERAPY SU + Metformin 1.7 SU + Pioglitazone 1.2 SU + Acarbose 1.3 Repaglinide + Metformin 1.4 Pioglitazone + Metformin 0.7 DPP-4 inhibitor + Metformin 0.7 DPP-4 inhibitor + Pioglitazone 0.7 Adapted from AACE Diabetes Mellitus Guidelines Endocr Pract 2007
73 Safety and Tolerability Risk of hypoglycemia Insulin secretagogues alpha-glucosidase Metformin inhibitors TZDs Insulin Weight gain GI side effects Lactic acidosis Edema 1 DeFronzo RA. Ann Intern Med 1999; 131: UKPDS. Lancet 1998; 352: Nesto RW, et al. Circulation 2003; 108:
74 Contraindications Renal insufficiency Sulfonylurea Meglitinide Biguanide AGI TZD Liver disease Inflammatory bowel disease Congestive heart failure Known hypersensitivity
75 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Since HbA1c reduction is the overriding goal, the precise combination used may not be as important as the glucose level achieved. There is no evidence that a specific combination is any more effective in lowering glucose levels or preventing complications than another. SU + Pio = SU + Metformin (Hanefield et al, 2004 & Nagasaka et al, 2004) SU + Met = SU + DPP-IV inhibitors (?)
76 UNITE PHILIPPINE CPG FOR DIABETES MELLITUS Statement The following patients must be referred to internists or diabetes specialists (endocrinologists or diabetologists) - Type 1 diabetes Moderate to severe hyperglycemia Co-morbid conditions (infections, acute CV events i.e. CHF or acute MI) Significant hepatic and renal impairment Women with diabetes who are pregnant
77 Clinical practice guidelines aim to help physicians and patients reach the best healthcare decisions. Steinbrook R. NEJM 2007
78 If you write it, and it is good, then they will follow. Keefer JH. Clin Chem 2001
79 THANK YOU
Clinical Practice Guidelines for Diabetes Management
Clinical Practice Guidelines for Diabetes Management Diabetes is a disease in which blood glucose levels are above normal. Over the years, high blood glucose damages nerves and blood vessels, which can
More informationAdult Diabetes Clinician Guide NOVEMBER 2017
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Adult Diabetes Clinician Guide Introduction NOVEMBER 2017 This evidence-based guideline summary is based on the 2017 KP National Diabetes Guideline.
More informationDiabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable?
Diabetes Guidelines in View of Recent Clinical Trials Are They Still Applicable? Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationChoosing a Diabetes Strategy Where to Start and Where to Go
Choosing a Diabetes Strategy Where to Start and Where to Go Erin Keely, MD, FRCPC; and Sharon Brez, RN, BScN, MA(Ed), CDE As presented at the University of Ottawa's 52nd Annual Refresher Course for Family
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationDiabetes and the Heart
Diabetes and the Heart Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 6, 2012 Outline Screening for diabetes in patients with CAD Screening for CAD in patients with
More informationAmerican Diabetes Association 2018 Guidelines Important Notable Points
American Diabetes Association 2018 Guidelines Important Notable Points The Standards of Medical Care in Diabetes-2018 by ADA include the most current evidencebased recommendations for diagnosing and treating
More informationDr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead
Dr Aftab Ahmad Consultant Diabetologist at Royal Liverpool University Hospital Regional Diabetes Network Lead Today s Presentation HbA1c & diagnosing Diabetes What is Impaired Glucose & IGR? Implications
More informationCurrent Diabetes Care for Internists:2011
Current Diabetes Care for Internists:2011 Petch Rawdaree, DM, MSc, DLSHTM Faculty of Medicine Vajira Hospital University of Bangkok Metropolis 19 th January 2011 ก ก 1. ก ก ก ก 2. ก ก ก ก ก 3. ก ก ก ก
More informationStandards of Medical Care in Diabetes 2016
Standards of Medical Care in Diabetes 2016 Care Delivery Systems 33-49% of patients still do not meet targets for A1C, blood pressure, or lipids. 14% meet targets for all A1C, BP, lipids, and nonsmoking
More informationDiabetes Mellitus: Implications of New Clinical Trials and New Medications
Diabetes Mellitus: Implications of New Clinical Trials and New Medications Estimates of Diagnosed Diabetes in Adults, 2005 Alka M. Kanaya, MD Asst. Professor of Medicine UCSF, Primary Care CME October
More informationGuidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010
Guidelines to assist General Practitioners in the Management of Type 2 Diabetes April 2010 Foreword The guidelines were devised by the Diabetes Day Centre in Beaumont Hospital in consultation with a number
More informationDiabetes Mellitus: Evaluation and Care Management
Diabetes Mellitus: Evaluation and Care Management Michael King, MD Assistant Professor Residency Program Director University of Kentucky Dept. of Family & Community Medicine Learning Objectives 1. Review
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationHEALTH SERVICES POLICY & PROCEDURE MANUAL
PAGE 1 of 5 PURPOSE To assure that DOP inmates with Diabetes are receiving high quality Primary Care for their condition. POLICY All DOP Primary Care Providers are to follow these guidelines when treating
More informationModified version focused on CCNC Quality Measures and Feedback Processes
Executive Summary: Standards of Medical Care in Diabetes 2010 Modified version focused on CCNC Quality Measures and Feedback Processes See http://care.diabetesjournals.org/content/33/supplement_1/s11.full
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationJanice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES
Janice Lazear, DNP, FNP-C, CDE DIAGNOSIS AND CLASSIFICATION OF DIABETES Objectives u At conclusion of the lecture the participant will be able to: 1. Differentiate between the classifications of diabetes
More informationMetabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology
Metabolic Syndrome Shon Meek MD, PhD Mayo Clinic Florida Endocrinology Disclosure No conflict of interest No financial disclosure Does This Patient Have Metabolic Syndrome? 1. Yes 2. No Does This Patient
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationPrevalence of Diabetes Mellitus and Pre-Diabetes in the Philippines: A Sub-study of the 7 th National Nutrition and Health Survey (2008)
Philippine Journal of Internal Medicine Original Paper Prevalence of Diabetes Mellitus and Pre-Diabetes in the Philippines: A Sub-study of the 7 th National Nutrition and Health Survey (2008) Cecilia A.
More informationQuick Reference Guide
2013 Clinical Practice Guidelines Quick Reference Guide (Updated November 2016) 416569-16 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Copyright 2016 Canadian Diabetes Association SCREENING
More informationDiabetes Update: Diabetes Management In Primary Care. Jonathon M. Firnhaber, MD, FAAFP
Diabetes Update: Diabetes Management In Primary Care Jonathon M. Firnhaber, MD, FAAFP Learning objectives 1. Critically evaluate the evidence emerging within diabetes research as it applies to recommendations
More informationObjectives. Objectives. Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015
Alejandro J. de la Torre, MD Cook Children s Hospital May 30, 2015 Presentation downloaded from http://ce.unthsc.edu Objectives Understand that the obesity epidemic is also affecting children and adolescents
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationApplication of the Diabetes Algorithm to a Patient
Application of the Diabetes Algorithm to a Patient Apply knowledge gained from this activity to improve disease management and outcomes for patients with T2DM and obesity Note: The cases in this deck represent
More informationDiabetes and Hypertension
Diabetes and Hypertension M.Nakhjvani,M.D Tehran University of Medical Sciences 20-8-96 Hypertension Common DM comorbidity Prevalence depends on diabetes type, age, BMI, ethnicity Major risk factor for
More informationHypertension Management in Diabetic Patients
Hypertension Management in Diabetic Patients Park, Chang G, MD, PhD Cardiovascular Center, Guro Hospital, Korea University Medical School Contents (Treatment of 2 Cases) Type 2 Diabetes Mellitus Hypertension
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationRCHC Clinical Guidelines Type 2 Diabetes; Adults
RCHC Clinical Guidelines Type 2 Diabetes; Adults Screening for diabetes in asymptomatic adults 1 Population: Aged > 45 years; Aged < 45 years who are overweight (BMI> 25kg/m 2 ) and have an additional
More informationHow to Reduce CVD Complications in Diabetes?
How to Reduce CVD Complications in Diabetes? Chaicharn Deerochanawong M.D. Diabetes and Endocrinology Unit Department of Medicine Rajavithi Hospital, Ministry of Public Health Framingham Heart Study 30-Year
More informationManagement of DM in Older Adults: It s not all about sugar! Who needs treatment for DM? Peggy Odegard, Pharm.D., BCPS, CDE
Management of DM in Older Adults: It s not all about sugar! Peggy Odegard, Pharm.D., BCPS, CDE Who needs treatment for DM? 87 year old, frail male with moderately severe dementia living in NH with persistent
More informationThe ABCs (A1C, BP and Cholesterol) of Diabetes
The ABCs (A1C, BP and Cholesterol) of Diabetes Gregg Simonson, PhD Director, Professional Training and Consulting International Diabetes Center; Adjunct Assistant Professor, University of Minnesota Department
More informationEugene Barrett M.D., Ph.D. University of Virginia 6/18/2007. Diagnosis and what is it Glucose Tolerance Categories FPG
Diabetes Mellitus: Update 7 What is the unifying basis of this vascular disease? Eugene J. Barrett, MD, PhD Professor of Internal Medicine and Pediatrics Director, Diabetes Center and GCRC Health System
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationStandards of Medical Care for Patients With Diabetes Mellitus
Standards of Medical Care for Patients With Diabetes Mellitus American Diabetes Association Originally approved 1988. Most recent review/revision, October 2002. Abridged from Diabetes Care 26 (Suppl. 1):S33
More informationCase study: Lean adult with no complications, newly diagnosed with type 2 diabetes
Case study: Lean adult with no complications, newly diagnosed with type 2 diabetes Authored by Clifford Bailey and James LaSalle on behalf of the Global Partnership for Effective Diabetes Management. The
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationIMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS
IMPROVED DIAGNOSIS OF TYPE 2 DIABETES AND TAILORING MEDICATIONS Dr Bidhu Mohapatra, MBBS, MD, FRACP Consultant Physician Endocrinology and General Medicine Introduction 382 million people affected by diabetes
More informationCURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013
CURRENT ISSUES IN DIABETES MANAGEMENT Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening for Diabetes 2013 BMI
More informationThe Diabetes Guidelines Trek: The Next Generation. Inpatient Diabetes Guidelines. Learning Objectives. Current Inpatient Guidelines
The Diabetes Guidelines Trek: The Next Generation J. Christopher Lynch, PharmD, BCACP Southern Illinois University Edwardsville School of Pharmacy Susan Cornell BS, PharmD, CDE, FAPhA, FAADE Midwestern
More informationThe Diabetes Link to Heart Disease
The Diabetes Link to Heart Disease Anthony Abe DeSantis, MD September 18, 2015 University of WA Division of Metabolism, Endocrinology and Nutrition Oswald Toosweet Case #1 68 yo M with T2DM Diagnosed DM
More information9/28/2012. Sponsored By: NDSU College of Pharmacy, Nursing and Allied Sciences
Sponsored By: NDSU College of Pharmacy, Nursing and Allied Sciences By PresenterMedia.com Faculty: Wendy Brown Pharm.D, PA-C, AE-C Associate Professor Pharmacy Practice About the Patient Clinical Coordinator
More informationFinding the sweet spot: Individualized targets for older adults with Type 2 DM
Finding the sweet spot: Individualized targets for older adults with Type 2 DM Samuel C. Durso, M.D., M.B.A. Mason F. Lord Professor of Medicine Director, Division of Geriatric Medicine and Gerontology
More informationMetabolic Syndrome and Chronic Kidney Disease
Metabolic Syndrome and Chronic Kidney Disease Definition of Metabolic Syndrome National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III Abdominal obesity, defined as a waist circumference
More informationMetformin should be considered in all patients with type 2 diabetes unless contra-indicated
November 2001 N P S National Prescribing Service Limited PPR fifteen Prescribing Practice Review PPR Managing type 2 diabetes For General Practice Key messages Metformin should be considered in all patients
More informationDiabetes is a chronic illness that requires
P O S I T I O N S T A T E M E N T Standards of Medical Care for Patients With Diabetes Mellitus AMERICAN DIABETES ASSOCIATION Diabetes is a chronic illness that requires continuing medical care and patient
More informationSTANDARDS OF MEDICAL CARE IN DIABETES 2014
STANDARDS OF MEDICAL CARE IN DIABETES 2014 I. CLASSIFICATION AND DIAGNOSIS Classification of Diabetes Type 1 diabetes β-cell destruction Type 2 diabetes Progressive insulin secretory defect Other specific
More informationBlood Pressure Measurement (children> 3 yrs)
Blood Pressure Measurement (children> 3 yrs) If initial BP elevated, repeat BP manually 2x and average, then classify Normal BP Systolic and diastolic
More informationStandards of Medical Care In Diabetes
Standards of Medical Care In Diabetes - 2017 Robert E. Ratner, MD, FACP, FACE Professor of Medicine Georgetown University School of Medicine Disclosed no conflict of interest Standards of Care Professional.diabetes.org/SOC
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More informationTreating the elderly patients with type 2 diabetes mellitus
Treating the elderly patients with type 2 diabetes mellitus Niki Katsiki MSc, PhD, MD, FRSPH IASO/EASO Scope Member EASD Diabetes & Cardiovascular Disease Group Member Member of the Executive Board of
More informationAddressing Addressing Challenges in Type 2 Challenges in Type 2 Diabetes Diabetes Speaker:
Addressing Challenges in Type 2 Diabetes Geneva Briggs, PharmD,, BCPS Addressing Challenges in Type 2 Diabetes Speaker: Dr. Geneva Clark Briggs, a board-certified Pharmacotherapy Specialist, received her
More informationAmerican Diabetes Association: Standards of Medical Care in Diabetes 2015
American Diabetes Association: Standards of Medical Care in Diabetes 2015 Synopsis of ADA standards relevant to the 11 th Scope of Work under Task B.2 ASSESSMENT OF GLYCEMIC CONTROL Recommendations: Perform
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationDiabetes Complications Guideline Based Screening, Management, and Referral
Diabetes Complications Guideline Based Screening, Management, and Referral Eric L. Johnson, M.D. Associate Professor Department of Family and Community Medicine Assistant Medical Director Altru Diabetes
More informationExecutive Summary: Standards of Medical Care in Diabetes 2010
E X E C U T I V E S U M M A R Y Executive Summary: Standards of Medical Care in Diabetes 2010 Current criteria for the diagnosis of diabetes A1C 6.5%: The test should be performed in a laboratory using
More informationOptimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden
Optimizing risk assessment of total cardiovascular risk What are the tools? Lars Rydén Professor Karolinska Institutet Stockholm, Sweden Cardiovascular Disease Prevention (CVD) Three Strategies for CVD
More informationDiscussion points. The cardiometabolic connection. Cardiometabolic Risk Management in the Primary Care Setting
Session #5 Cardiometabolic Risk Management in the Primary Care Setting Sonja Reichert, MD MSc FCFP FACPM Betty Harvey, RNEC BScN MScN Amanda Mikalachki, RN BScN CDE S Discussion points Whom should we be
More informationRISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES
RISK FACTORS OR COMPLICATIONS AND RECOMMENDED TREATMENT GOALS AND FREQUENCY OF EVALUATION FOR ADULTS WITH DIABETES Risk Factors or Complications Glycemic Control Fasting & Capillary Plasma Glucose Anti-platelet
More informationDM in OPD for Internist. Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 28 Oct 2013
DM in OPD for Internist Rungnapa Laortanakul, MD Maharat Nakhon Ratchasima hospital 28 Oct 2013 Outlines DM management GDM Case Somjit is a 43-year-old woman Check-up No abnormal symptom Laboratory FBS
More informationScreening and Diagnosis of Diabetes Mellitus in Taiwan
Screening and Diagnosis of Diabetes Mellitus in Taiwan Hung-Yuan Li, MD, MMSc, PhD Attending Physician, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan Associate Professor,
More informationCURRENT CONTROVERSIES IN DIABETES CARE
CURRENT CONTROVERSIES IN DIABETES CARE Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Diabetes Mellitus: U.S. Impact
More informationDiabetes Review Chris Paras, D.O. Assistant Prof of Medicine, NYIT & Touro COM Designated Institutional Official & Assoc. Clinical Dean, Brookdale
Diabetes Review Chris Paras, D.O. Assistant Prof of Medicine, NYIT & Touro COM Designated Institutional Official & Assoc. Clinical Dean, Brookdale University Hospital Diabetes Care 2018 Jan; 41 Objectives
More informationhypertension Head of prevention and control of CVD disease office Ministry of heath
hypertension t. Samavat MD,Cadiologist,MPH Head of prevention and control of CVD disease office Ministry of heath RECOMMENDATIONS FOR HYPERTENSION DIAGNOSIS, ASSESSMENT, AND TREATMENT Definition of hypertension
More informationWhy Do We Care About Prediabetes?
Why Do We Care About Prediabetes? Complications of Diabetes Diabetic Retinopathy Leading cause of blindness in adults 1,2 Diabetic Nephropathy Leading cause of Kidney failure Stroke 2- to 4-fold increase
More informationManagement of Diabetes Mellitus: A Primary Care Perspective
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationAmerican Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications
American Diabetes Association Standards of Medical Care in Diabetes 2017: Focus on Complications Juan Pablo Frias, M.D., FACE President and CEO, National Research Institute, Los Angeles, CA Clinical Faculty,
More informationType 2 Diabetes. Stopping Smoking. Consider referral to smoking cessation. Consider referring for weight management advice.
Type 2 Diabetes Stopping Smoking Consider referral to smoking cessation BMI > 25 kg m² Set a weight loss target of a 5-10% reduction Consider referring for weight management advice Control BP to
More information第十五章. Diabetes Mellitus
Diabetes-1/9 第十五章 Diabetes Mellitus 陳曉蓮醫師 2/9 - Diabetes 羅東博愛醫院 Management of Diabetes mellitus A. DEFINITION OF DIABETES MELLITUS Diabetes Mellitus is characterized by chronic hyperglycemia with disturbances
More informationOld oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy
Old oral antidiabetic agents in the armamentarium of diabetes mellitus treatment: Safety and efficacy Melpomeni Peppa Assistant Professor of Endocrinology 2 nd Dept of Internal Medicine-Propaedeutic, Athens
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationDiabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018
Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018 Points to Ponder ASCVD is the leading cause of morbidity
More informationUtah Diabetes Practice Recommendations Diabetes Management for Adults
Utah Diabetes Practice Recommendations Diabetes Management for Adults 2011 Panel Sarah Woolsey, MD, Chair, Family Medicine HealthInsight Wayne Cannon, MD, Pediatrics Intermountain Healthcare Roy Gandolfi,
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationInernal Medicine by Prof. El Sayed Abdel Fatah Eid. Diabetes Mellitus. Prof. El Sayed Abdel Fattah Eid. Lecturer of Internal Medicine Delta University
Diabetes Mellitus By Prof. El Sayed Abdel Fattah Eid Lecturer of Internal Medicine Delta University (Diabetes Mellitus) Definition: Diabetes mellitus comprises a heterogeneous group of metabolic diseases
More informationManagement of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test
Management of Diabetes Mellitus: A Primary Care Perspective Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest Screening
More informationPersonal Diabetes Passport
Personal Diabetes Passport Contact information: Name: Physician: Diabetes Education Centre: Dietitian: Ophthalmologist: Chiropodist: Type of Diabetes: Type 1 (T1DM) Increased risk for diabetes Type 2(T2DM)
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationExecutive Summary: Standards of Medical Care in Diabetes 2009
Executive Summary Executive Summary: Standards of Medical Care in Diabetes 2009 Current Criteria for the Diagnosis of Diabetes Fasting plasma glucose (FPG) 126 mg/dl (7.0 mmol/l). Fasting is defined as
More informationQuick Reference Guide
2018 Clinical Practice Guidelines Quick Reference Guide 416569-18 guidelines.diabetes.ca diabetes.ca 1-800-BANTING (226-8464) Screening and Diagnosis Assess risk ANNUALLY if: Family history (First-degree
More informationUpdate on Diabetes Standards-What Community Physicians Should Know. Kevin Miller D.O.
Update on Diabetes Standards-What Community Physicians Should Know. Kevin Miller D.O. Know The ABC Targets A1C BP LDL Cholesterol AACE Recommendations for A1C Testing A1C levels may be misleading in several
More informationManagement of Diabetes
Management of Diabetes Mellitus: Which Drugs for Which Patients? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine baron@medicine.ucsf.edu Disclosure No relevant financial relationships
More informationIn providing the best care for
An Evaluation of the Current Type 2 Diabetes Guidelines: Where They Converge and Diverge Evelyn Tan, PharmD, Jennifer Polello, MPA, MCES, and Lisa J. Woodard, PharmD, MP In providing the best care for
More informationDiabetic Nephropathy 2009
Diabetic Nephropathy 2009 Michael T McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetic Nephropathy Clinical Stages Hyperfunction
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationThe National Diabetes Prevention Program in Washington State March 2012
The National Diabetes Prevention Program in Washington State March 2012 Session Objectives 1. Overview of pre-diabetes. 2. Describe the Diabetes Prevention Program (DPP). 3. Eligibility for the DPP. 4.
More informationDiabetes Mellitus: A Cardiovascular Disease
Diabetes Mellitus: A Cardiovascular Disease Nestoras Mathioudakis, M.D. Assistant Professor of Medicine Division of Endocrinology, Diabetes, & Metabolism September 30, 2013 1 The ABCs of cardiovascular
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationDiabetes: Across the Lifespan Friday, October 17, Obesity, Insulin Resistance and Type 2 Diabetes Cardiovascular Risks in Children.
Diabetes: Across the Lifespan Friday, October 17, 2014 Obesity, Insulin Resistance and Type 2 Diabetes Cardiovascular Risks in Children. Don P. Wilson, M.D., FNLA Diplomate, Am Brd of Clinical Lipidology
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationPresenter Disclosure Information
Prediabetes & Type 2 Diabetes Prevention Cari Ritter, PA-C Presenter Disclosure Information In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationClinical Practice Guidelines
Clinical Practice Guidelines Diabetes Objective The purpose is to guide the appropriate diagnosis and management of Diabetes. This guideline is designed to assist the clinician by providing a framework
More informationDiabetes Summary of Medical Guidelines
Diabetes Summary of Medical Guidelines Key concepts in setting glycemic controls: goals should be individualized; certain populations (children, pregnant women, and elderly) require special considerations;
More informationABFM Diabetes SAM Part 4
ABFM Diabetes SAM Part 4 37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular
More informationFUNDING: MICIS mandated by Maine Legislature, funded by fees collected from pharmaceutical companies as a cost of doing business in the state.
GOAL: To improve clinical outcomes by delivering upto-date, evidence-based prescribing information, using data and guidelines developed by noncommercial sources FUNDING: MICIS mandated by Maine Legislature,
More informationCE on SUNDAY Newark, NJ October 18, 2009
CE on SUNDAY Newark, NJ October 18, 2009 Date: Sunday, October 18, 2009 Time: 2:45 PM 3:45 PM Location: Sheraton Newark Airport Hotel Title: Speaker(s): Addressing Challenges in Type 2 Diabetes ACPE #
More information